Zobrazeno 241 - 250
of 290
pro vyhledávání: ''
Autor:
Mina Iwanishi, Satoru Hagiwara, Hirokazu Chishina, Tomohiro Minami, Toshiharu Sakurai, Masatoshi Kudo, Kazuomi Ueshima, Yoriaki Komeda, Masahiro Takita, Tadaaki Arizumi, Tomohiro Watanabe, Hiroshi Ida, Naoshi Nishida, Yasunori Minami
Publikováno v:
Oncology. 92
Introduction: Recently, the treatment of chronic hepatitis C has markedly advanced. A phase III clinical study of combination therapy with sofosbuvir (SOF) and ledipasvir (LDV) was conducted in Japan, and the additive therapeutic effects were reporte
Autor:
Friedrich A. Schöndube, Kirsten Reuter-Jessen, Johanna Arnemann, Tobias Overbeck, R. Waldmann-Beushausen, Bernhard C. Danner, Lorenz Trümper
Publikováno v:
Oncology. 93(4)
Background: ATP-binding cassette transport protein A3 (ABCA3) is expressed in non-small cell lung cancer (NSCLC). We hypothesize that high-level ABCA3 expression may have a negative prognostic impact in patients with NSCLC. Methods: In 89 patients wi
Autor:
Tetsuji Takayama, Toshihito Tanahashi, Eriko Aoyagi, Naoki Muguruma, Tetsuo Kimura, Shinji Kitamura, Kazuhito Rokutan, Yasuhiro Mitsui, Tadahiko Nakagawa, Koichi Okamoto, Hiroshi Miyamoto
Publikováno v:
Oncology. 93(2)
Objectives: The aim of this study was to identify biomarkers for predicting the efficacy of docetaxel, cisplatin, and S-1 (DCS) therapy for advanced gastric cancer using microarrays of biopsy specimens before chemotherapy. Methods: Nineteen samples w
Autor:
Stefan Kudlacek, Nicole Kraischits, Paul Schramek, Michael Lamche, Thomas Kunit, Dora Niedersüss-Beke, Reinhard Böhm, Wolfgang Loidl, Thomas Puntus, Johannes G. Meran, Birgit Grünberger
Publikováno v:
Oncology. 93(1)
Background: Neoadjuvant chemotherapy with methotrexate-vinblastine-doxorubicin-cisplatin (MVAC) is the standard of care for muscle-invasive urothelial bladder cancer. Gemcitabine plus cisplatin (GC) shows similar efficacy with less toxicity in the me
Autor:
Gota Saito, Hiroko Kamata, Toshiyuki Suzuki, Akira Tanaka, Sotaro Sadahiro, Hiroshi Miyakita, Kazutake Okada
Publikováno v:
Oncology. 92(5)
Objectives: Serum carcinoembryonic antigen (CEA) has been widely used for postoperative surveillance for colorectal cancer. However, serum CEA has a poor diagnostic accuracy for detecting recurrence. We tested the hypothesis that determining cutoff v
Autor:
Enrico Cortesi, Giacomo Barchiesi, Alain Gelibter, Valentina Magri, Salvatore Caponnetto, Giovanni Maria Iannantuono
Publikováno v:
Oncology. 93(1)
Background/Aims: Prolactin (PRL) is a peptide hormone and several studies have demonstrated its role as a cytokine in human T cell-mediated immunity. We are unaware if PRL is a positive or negative immunomodulator, but its effects on the regulation o
Autor:
Alessia Romito, Claudia Marchetti, Ludovico Muzii, Serena Maria Boccia, Pierluigi Benedetti Panici, Francesca De Felice, Violante Di Donato, Marco Monti, Laura Vertechy, Innocenza Palaia, Angela Musella
Publikováno v:
Oncology. 93(6)
Objective: The aim of this study was to assess the efficacy and tolerability of trabectedin given every 10 days as a single agent in recurrent ovarian cancer after 3 prior regimens. Method: Trabectedin 0.6 mg/m2 was administered as a 3-h infusion eve
Autor:
Michiyo Saimura, Tsuyoshi Saito, Satoshi Toyoshima, Uhi Toh, Nobuyuki Arima, Maki Tanaka, Reiki Nishimura, Toshihiro Tanaka, Toshihiro Koga, Kazuhisa Katayama, Yuichiro Kai, Kazuo Tamura, Megumi Teraoka, Shoshu Mitsuyama, Satoshi Hasegawa, Yasuyo Ohi, Kaname Kurashita, Kazuo Shimada, Hidekazu Todoroki, Yasuhiro Okumura
Publikováno v:
Oncology. 93(1)
Objective: The aim of this study was to investigate the correlation between human epidermal growth factor receptor 2 (HER2)-related biomarkers and the treatment outcomes using lapatinib plus capecitabine (LC) and to evaluate the influence of the estr
Publikováno v:
Oncology. 93(2)
Objectives: Evidence for complementary therapies as important strategies to relieve cancer treatment-associated symptoms is increasing. Mostly, these complementary therapies start at the end of adjuvant treatments, resulting in a long delay until the
Autor:
Makoto Yamasaki, Shigeyuki Tamura, Motohiro Hirao, Kenji Kobayashi, Hiroshi Miyata, Masayuki Shinkai, Yuichiro Doki, Masaaki Motoori, Takushi Yasuda, Osamu Shiraishi, Tomoki Makino, Kazumasa Fujitani, Masahiko Yano, Yutaka Kimura
Publikováno v:
Oncology. 92(2)
Background: Neoadjuvant chemotherapy for resectable advanced esophageal squamous cell carcinoma (ESCC) requires reassessment. We have conducted a trial aiming at the comparison between DCF and ACF concerning perioperative adverse events. Methods: Pat